PosterSessionOnline

INTERNATIONAL LIVER CANCER ASSOCIATION

International Liver Cancer Association 17th Annual Conference

7-9 September, Amsterdam

N. Poster

Poster title

Applicant name

Status


P-01	Multimodal and spatial analysis of tumour-immune microenvironment in steatosis-driven hepatocellular carcinoma	Aldo Prawira	Received

P-02	Inhibition of PARP-1 in KRAS-mutated intrahepatic cholangiocarcinoma exerts positive effects and is mediated by CHK1 kinase	Darko Castven	Received

P-03	Hypoxia promotes adenosine efflux to establish the immunosuppressive microenvironment in liver cancer	Carmen Wong	Received

P-04	Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma	Binghua Li	Received

P-05	Integrated genomic analysis refines molecular classifications of hepatocellular carcinoma based on LICA-FR cohort of 529 samples	Long Pan	Received

P-06	The senescent secretome drives the re-emergence of the fetal receptor PLVAP on human hepatic endothelium to promote monocyte transmigration.	Shishir Shetty	Received

P-07	Inactivation of histone chaperone complex CAF-1 elicits intrinsic anti-cancer immunity through activating the cytosolic DNA and dsRNA sensing pathways in hepatocellular carcinoma	Chun-Ming Wong	Received

P-08	Outcome of Targeting ATR in High Replication Stress murine HCC	JING FANG	Received

P-09	Genetic and pathologic features of papillary neoplasms of human biliary system of intrahepatic and extrahepatic bile ducts and gallbladder	Young Nyun Park	Received

P-13	Financial and Psychological Burden of HCC Surveillance in Patients with Cirrhosis	Amit Singal	Received

P-14	Achievement of Cancer and Drug-free Status by Atezolizumab Plus Bevacizumab Followed by Curative Conversion in Patients with TACE-Unsuitable, Intermediate-stage HCC: A Multicenter Proof-of-Concept Study	Masatoshi Kudo	Received

P-15	VETC (vessel that encapsulate tumor cluster) EVALUATED IN LIVER BIOPSY PREDICTS ANTI-ANGIOGENIC BENEFIT IN ADVANCED HCC	Luca Di Tommaso	Received

P-17	Association with body mass index and risk of hepatocellular carcinoma according to liver disorder status	HEEJAE JUNG	Received

P-19	Drug-eluting beads vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A Randomized Clinical Trial	Jun-Hui Sun	Received

P-20	Prospective study of surveillance non-contrast abbreviated MRI for hepatocellular cancer in patients with suboptimal hepatic visualisation on ultrasound	Mathew Vithayathil	Received

P-22	Genomic characteristics of hepatocellular carcinoma patients with response to sorafenib	Sun Young Yim	Received

P-24	Cytokine levels and circulating DNA in plasma could be used as serological biomarkers of response to immunotherapy in hepatocellular carcinoma	Beatriz Mínguez	Received

P-25	Preliminary Safety Results of a Phase 1/2 Open-label Study on an Anti-GPC3 T-cell Engager, SAR444200, in Patients with Advanced Solid Tumors	Asma Kefsi	Received

P-27	Constructing and Experimentally Validating a Disulfidptosis-related Ferroptosis Gene-driven Machine Learning Prognostic Risk Model for Liver Cancer	Cong Zhang	Received

P-28	Serine utilization and generation of different lipid species influence the response of hepatocellular carcinoma to lipid depletion	Bichitra Paul	Received

P-31	B-CATENIN PATHWAY MUTATIONS PREDICT FAVORABLE OUTCOMES AFTER TRANSARTERIAL CHEMOEMBOLIZATION IN UNRESECTABLE HEPATOCELLULAR CARCINOMA	Kelley Weinfurtner	Received

P-32	Lipid-Associated TREM2 Macrophages Mediates Immunosuppressive Microenvironment in Liver Metastasis of Colorectal Cancer	Pengxiang Wang	Received

P-33	Identification of novel phosphoproteomic biomarkers in patients with advanced hepatocellular carcinoma (HCC)	Federico Pedicona	Received

P-34	Evaluation of Src family of tyrosine kinases and their potential as molecular targets in overcoming liver cancer heterogeneity	Loraine Kay Cabral	Received

P-35	Inflammation induced IgA upregulates PD-L1 in cancer associated fibroblasts of HCC and attenuates CD8 T cell function	Sung Woo Cho	Received

P-36	Nanosecond pulsed electric field ablation of sequential endothelial progenitor cell-directed endothelial inhibitor/suicide fusion gene for the treatment of hepatocellular carcinoma	Li Jing	Received

P-37	Combinations of fostrox (MIV-818), a novel nucleotide prodrug, with lenvatinib or sorafenib shows increased efficacy in nonclinical hepatocellular carcinoma (HCC) models in vivo	Fredrik Oberg	Received

P-38	Impact of exosomal miR-4669 on tumor cell behavior and immunosuppressive tumor microenvironment in hepatocellular carcinoma	Toshiaki Nakano	Received

P-39	New insight in HCC immuno-vascular microenvironment: interplay between tumoral macrophages and VETC	Camilla De Carlo	Received

P-40	Functional dissection of immune infiltrate reveals that HCC enriched VETC vascular phenotype is characterized by the presence of exhausted T cells.	Barbara Durante	Received

P-41	Poor sorafenib response in hepatocellular carcinoma is mediated by hypoxia-associated 14-3-3 scaffolding proteins with observed alterations in immune micromilieu	Jovana Castven	Received

P-42	Synergistic antitumor activity of lenvatinib and lipophilic statins in hepatocellular carcinoma	Hyeyeon Hong	Received

P-44	GDF11 reduces aggressive behavior provided by tumor-associated macrophages on HCC-derived cells.	Oscar Alejandro Escobedo Calvario	Received

P-45	Effect of Zinc Acexamate treatment in hepatocellular carcinoma in vitro and in vivo models	Beatriz Mínguez	Received

P-46	Identification of the epidrivers facilitating hepatocellular carcinoma recurrence	Hyun Goo Woo	Received

P-47	Gene regulatory network analysis on snRNAseq revealed key regulators for hepatocellular carcinoma progression	Su Jong Yu	Received

P-48	Lenvatinib induced cell death of hepatocellular carcinoma by increasing HIF-a degradation under hypoxic condition	Sung Won Chung	Received

P-50	CD73 expression on liver endothelium is promoted by tumour associated stimuli and could contribute to the immunosuppressive microenvironment in hepatocellular carcinoma	Rosemary Faulkes	Received

P-51	Fructose promotes chemoresistance through the induction of a metabolic rewiring in liver cancer cells and a KHK-A/p27 non-canonical pathway.	Lisette Chávez Rodríguez	Received

P-52	LI-RADS classification of proliferative hepatocellular carcinomas and its implication on prognosis	Subin Heo	Received

P-54	The Outcomes of Patients with Hepatocellular Carcinoma and with Child-Turcotte-Pugh Class B	Chia Chu Fu	Received

P-55	Prediction of Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients following HBsAg seroclearance	Jonggi Choi	Received

P-56	Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC	Federico Piñero	Received

P-58	Tumor response-based nomogram for ion of patients with hepatocellular carcinoma benefitting from drug-eluting bead transarterial chemoembolization	Cong Zhang	Received

P-59	Effect of chemotherapeutic agents on acute kidney injury in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: doxorubicin versus cisplatin	Won Sohn	Received

P-60	Treatment outcomes in patients with advanced fibrolamellar hepatocellular carcinoma: analysis of clinical characteristics and radiomics phenotypes	Leonardo da Fonseca	Received

P-63	Implication of patients experience in the liver cancer multidisciplinary approach	Gemma Iserte	Received

P-65	Sarcopenia affects the therapeutic efficacy of immunotherapy for advanced Hepatocellular carcinoma.	Takuya Kuwashiro	Received

P-68	Consistent efficacy of Hepatic Artery Infusion Chemotherapy irrespective of PD-L1 positivity in unresectable hepatocellular carcinoma	Ji Hoon Kim	Received

P-69	Differences in Outcomes Between Screen-Detected and Non-Screen Detected Hepatocellular Carcinoma	Darine Daher	Received

P-71	Correlates and Outcomes of CT or MRI-based Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis	Darine Daher	Received

P-72	Clinical Performance of GAAD and GALAD Algorithmic Scores for Hepatocellular Carcinoma (HCC) surveillance in Patients with Chronic Hepatitis	Ming-Lung Yu	Received

P-74	Discrepancy between the real clinical status of patients with HCC and expectations from HCC surveillance: a single center study	Jiwoong Jang	Received

P-75	Peripheral immune markers can detect hepatocellular carcinoma in blood in a Latin American cohort	Andre Boonstra	Received

P-76	Evaluation of the Accuracy of Imaging Diagnosis for Hepatocellular Carcinoma in Chronic Hepatitis C Patients without Liver Cirrhosis	Jihyun An	Received

P-80	Differentiation of Primary Malignant Vascular Tumors using CT and Gadoxetate-enhanced Liver MRI	So Yeon Kim	Received

P-81	Pan-viral serology uncovers distinct virome patterns among hepatocellular carcinoma and control populations	Whitney Do	Received

P-82	Role of Tumor Markers in Diagnosing Recurrent Hepatocellular Carcinoma after Curative Resection	Jeong Ah Hwang	Received

P-83	Performance of tumor-specific microRNAs as plasma biomarkers of hepatocellular carcinoma in patients with liver cirrhosis	Robin Zenlander	Received

P-85	Five-year on-treatment parameters-based model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir-treated patients	Yeonjung Ha	Received

P-86	Evaluating performance of aMAP score in predicting hepatocellular carcinoma development over a two-year period in cirrhosis patients	Avisnata Das	Received

P-89	Early detection of hepatocellular carcinoma using urinary metabolomic biomarkers in an Australian Aboriginal population.	Paula Binks	Received

P-90	Physician and patient survey of practices and perspectives in the surveillance and diagnosis of hepatocellular carcinoma (HCC) in Asia: unmet needs in the real world	Iain Murdoch	Received

P-91	IMbrave050: Phase 3 study of adjuvant atezolizumab bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation	Elyse Viana	Received

P-92	Risk of Gastrointestinal Bleeding in Patients Receiving AtezolizumabBevacizumab Treatment for Hepatocellular Carcinoma	Jonggi Choi	Received

P-93	Real-world (RW) systemic treatment patterns in US patients (pts) with hepatocellular carcinoma (HCC): 20202022	Rego Team	Received

P-94	Systemic Treatment in Child Pugh B Patients with Hepatocellular Carcinoma	Kevin Mok	Received

P-95	Semaglutide, but not lanifibranor, promotes tumor regression in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC	Denise Oró	Received

P-96	Metabolic dysfunction associated fatty liver disease and the risk of hepatocellular carcinoma	BYEONGGEUN SONG	Received

P-97	Randomized phase II trial to assess safety and efficacy of regorafenib in patients with advanced hepatocellular carcinoma who were not included in the RESORCE trial: REGAIN trial	Keisuke Koroki	Received

P-98	A Study on the Sequence of Systemic Treatment in Hepatocellular Carcinoma	Kevin Mok	Received

P-99	Macrotrabecular-Massive pattern is associated with aggressive factors, but it is not an independent predictor of tumor recurrence and overall survival in patients with hepatocelular carcinoma treated with liver resection	Ezequiel Mauro	Received

P-100	Validation of Baveno-VII criteria for clinically significant portal hypertension in patients with compensated advanced chronic liver disease	BYEONGGEUN SONG	Received

P-101	The predictive value of liver volume on hepatic decompensation and the long-term effects of stereotactic body radiation therapy on hepatic decompensation	JINHONG JUNG	Received

P-102	A prospective study to evaluate the safety and efficacy of lenvatinib in patients with advanced hepatocellular carcinoma to maximise its potential in current practice	Kazufumi Kobayashi	Received

P-104	Real-time US-CT/MR Fusion Imaging-guided Anatomical Ablation for Small Hepatocellular Carcinomas Using Multiple Applicators: A Preliminary Study	Jae Hyun Kim	Received

P-105	Glypican-3-targeted radiopharmaceutical therapy for hepatocellular carcinoma: Preclinical characterization of a novel peptide radioligand	Fanching Lin	Received

P-107	A Multicenter Propensity Score Matching Analysis of the Clinical Outcome of Atezolizumab/Bevacizumab and Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Comparative study	Hee Sun Cho	Received

P-108	Single arm study to evaluate the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma patients in Japanese real-world practice; focusing on the complement of the REACH-2 study: R-evolution trial	Kazufumi Kobayashi	Received

P-109	Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance	Marco Sanduzzi Zamparelli	Received

P-110	Lung-specific response to atezolizumab plus bevacizumab is associated with overall survival in patients with lung metastasis from hepatocellular carcinoma	Ju Hyun Shim	Received

P-111	Clinical Outcomes of Stereotactic Body Radiation Therapy Alone versus Stereotactic Body Radiation Therapy after Incomplete Transarterial Chemoembolization for a Single Small (= 5 cm) Recurrent Hepatocellular Carcinoma	JINHONG JUNG	Received

P-112	Metastasectomy versus stereotactic body radiation therapy for pulmonary oligometastasis from hepatocellular carcinoma: a propensity score-weighted analysis	Sang Min Yoon	Received

P-113	Palliative care in patients with BCLC-D hepatocellular carcinoma not indicated for liver transplantation: results of a survey among Italian hepatologists and palliative care physicians.	Lorenzo Canova	Received

P-114	Portal-hypertension parameters are associated with transplantation free survival and ascites occurrence in patients with hepatocellular carcinoma treated by external radiotherapy	Héloïse Giudicelli	Received

P-115	Significance of autoantibody assay in patients receiving atezolizumab and bevacizumab combination therapy for unresectable hepatocellular carcinoma	Hitomi Takada	Received

P-117	Value based Healthcare: Patient perception of the liver cancer Advanced Practice Nurse care at the Barcelona Clinic Liver Cancer	Neus Llarch	Received

P-118	Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation	Jai Young Cho	Received

P-119	A real-world comparative analysis of atezolizumab plus bevacizumab and transarterial chemoembolization plus radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombosis	Jong Young Choi	Received

P-123	Liver-directed combined radiotherapy for downstaging of over the Milan advanced hepatocellular carcinoma converting to liver transplantation	jinsil seong	Received

P-124	Comparative Analysis of combination therapy (Atezolizumab bevacizumab) and hepatic artery infusion chemotherapy in Unresectable Hepatocellular carcinoma: A multi-center study	Ji Hoon Kim	Received

P-126	The efficacy and safety of Toripalimab combined with Sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study	Xin-Rong Yang	Received

P-127	Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma	Judith Land	Received

P-128	Association of alcohol consumption with liver cancer and all-cause mortality in chronic hepatitis B patients without cirrhosis	Beom Kyung Kim	Received

P-129	FGFR2 Pathway Activation Beyond The Alteration of FGFR Receptor in Intrahepatic Cholangiocarcinoma	Chiara Deiana	Received

P-130	Differential risk of hepatic events during immune checkpoint inhibitor treatment between hepatocellular carcinoma and other malignancies	Yi-Hsiang Huang	Received

P-131	The expression of Aurora kinase A in hepatocarcinogenesis and its role in Programmed DeathLigand 1 regulation	Luca Grisetti	Received

P-132	Weakly supervised primary liver cancer classification from routine tumour biopsy: a proof of concept	Aurélie Beaufrère	Received

International Liver Cancer Association 17th Annual Conference

7-9 September, Amsterdam

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 06/09/2023 TO 07/09/2024

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access